For example, canakinumab, an IL-1β inhibitor, has shown potential in reducing cardiovascular events by dampening inflammatory responses, a promising strategy for improving long-term outcomes in CKD patients [190,191]. The gene discussed is IL1B; the disease is chronic kidney disease.